Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan

Shinsuke Yasuda, Tatsuya Atsumi, Sanae Shimamura, Kota Ono, Keiju Hiromura, Kenei Sada, Masaaki Mori, Syuji Takei, Yasushi Kawaguchi, Naoto Tamura, Yoshinari Takasaki

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives. Mycophenolate mofetil (MMF) is used as one of the standard induction/maintenance protocols for lupus nephritis (LN). However, MMF has not been approved for treating LN in any country, resulting in worldwide off-label use of this immunosuppressant. In order to clarify the real-world use of MMF as a treatment for LN in Japan, Japan College of Rheumatology surveyed the use of MMF in daily clinical practice. Methods. Adult patients with LN who visited enrolled hospitals from October 2008 to September 2013 were surveyed for the initial, maximum, and maintenance doses of MMF. The safety and efficacy of MMF were retrospectively evaluated. Results. One hundred and thirty-seven LN patients including 116 females were enrolled. The median of initial, maximum, and maintenance doses of MMF were 1.0 g/day, 1.5 g/day, and 1.0 g/day, respectively. Sixty-one adverse events were reported in 39 patients during the follow-up period. Median urine protein level decreased from 1.89 g/gCr to 0.21 g/gCr, meanC3 level increased from 66.4 mg/dl to 80.3 mg/dl, and median anti-DNA antibody titer decreased from 40.6 IU/ml to 10.6 IU/ml. Conclusion. MMF was commonly used for the treatment of adult LN patients with acceptable efficacy and safety in Japan.

Original languageEnglish
Pages (from-to)854-857
Number of pages4
JournalModern Rheumatology
Volume25
Issue number6
DOIs
Publication statusPublished - Sep 8 2015

Fingerprint

Mycophenolic Acid
Lupus Nephritis
Japan
Off-Label Use
Safety
Antinuclear Antibodies
Rheumatology
Immunosuppressive Agents
Maintenance
Urine

Keywords

  • Induction therapy
  • Mycophenolate mofetil
  • Mycophenolic acid
  • Proliferative lupus nephritis
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan. / Yasuda, Shinsuke; Atsumi, Tatsuya; Shimamura, Sanae; Ono, Kota; Hiromura, Keiju; Sada, Kenei; Mori, Masaaki; Takei, Syuji; Kawaguchi, Yasushi; Tamura, Naoto; Takasaki, Yoshinari.

In: Modern Rheumatology, Vol. 25, No. 6, 08.09.2015, p. 854-857.

Research output: Contribution to journalArticle

Yasuda, S, Atsumi, T, Shimamura, S, Ono, K, Hiromura, K, Sada, K, Mori, M, Takei, S, Kawaguchi, Y, Tamura, N & Takasaki, Y 2015, 'Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan', Modern Rheumatology, vol. 25, no. 6, pp. 854-857. https://doi.org/10.3109/14397595.2015.1031444
Yasuda, Shinsuke ; Atsumi, Tatsuya ; Shimamura, Sanae ; Ono, Kota ; Hiromura, Keiju ; Sada, Kenei ; Mori, Masaaki ; Takei, Syuji ; Kawaguchi, Yasushi ; Tamura, Naoto ; Takasaki, Yoshinari. / Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan. In: Modern Rheumatology. 2015 ; Vol. 25, No. 6. pp. 854-857.
@article{b068d6372da2473287adf4a5cfe8aef9,
title = "Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan",
abstract = "Objectives. Mycophenolate mofetil (MMF) is used as one of the standard induction/maintenance protocols for lupus nephritis (LN). However, MMF has not been approved for treating LN in any country, resulting in worldwide off-label use of this immunosuppressant. In order to clarify the real-world use of MMF as a treatment for LN in Japan, Japan College of Rheumatology surveyed the use of MMF in daily clinical practice. Methods. Adult patients with LN who visited enrolled hospitals from October 2008 to September 2013 were surveyed for the initial, maximum, and maintenance doses of MMF. The safety and efficacy of MMF were retrospectively evaluated. Results. One hundred and thirty-seven LN patients including 116 females were enrolled. The median of initial, maximum, and maintenance doses of MMF were 1.0 g/day, 1.5 g/day, and 1.0 g/day, respectively. Sixty-one adverse events were reported in 39 patients during the follow-up period. Median urine protein level decreased from 1.89 g/gCr to 0.21 g/gCr, meanC3 level increased from 66.4 mg/dl to 80.3 mg/dl, and median anti-DNA antibody titer decreased from 40.6 IU/ml to 10.6 IU/ml. Conclusion. MMF was commonly used for the treatment of adult LN patients with acceptable efficacy and safety in Japan.",
keywords = "Induction therapy, Mycophenolate mofetil, Mycophenolic acid, Proliferative lupus nephritis, Systemic lupus erythematosus",
author = "Shinsuke Yasuda and Tatsuya Atsumi and Sanae Shimamura and Kota Ono and Keiju Hiromura and Kenei Sada and Masaaki Mori and Syuji Takei and Yasushi Kawaguchi and Naoto Tamura and Yoshinari Takasaki",
year = "2015",
month = "9",
day = "8",
doi = "10.3109/14397595.2015.1031444",
language = "English",
volume = "25",
pages = "854--857",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan

AU - Yasuda, Shinsuke

AU - Atsumi, Tatsuya

AU - Shimamura, Sanae

AU - Ono, Kota

AU - Hiromura, Keiju

AU - Sada, Kenei

AU - Mori, Masaaki

AU - Takei, Syuji

AU - Kawaguchi, Yasushi

AU - Tamura, Naoto

AU - Takasaki, Yoshinari

PY - 2015/9/8

Y1 - 2015/9/8

N2 - Objectives. Mycophenolate mofetil (MMF) is used as one of the standard induction/maintenance protocols for lupus nephritis (LN). However, MMF has not been approved for treating LN in any country, resulting in worldwide off-label use of this immunosuppressant. In order to clarify the real-world use of MMF as a treatment for LN in Japan, Japan College of Rheumatology surveyed the use of MMF in daily clinical practice. Methods. Adult patients with LN who visited enrolled hospitals from October 2008 to September 2013 were surveyed for the initial, maximum, and maintenance doses of MMF. The safety and efficacy of MMF were retrospectively evaluated. Results. One hundred and thirty-seven LN patients including 116 females were enrolled. The median of initial, maximum, and maintenance doses of MMF were 1.0 g/day, 1.5 g/day, and 1.0 g/day, respectively. Sixty-one adverse events were reported in 39 patients during the follow-up period. Median urine protein level decreased from 1.89 g/gCr to 0.21 g/gCr, meanC3 level increased from 66.4 mg/dl to 80.3 mg/dl, and median anti-DNA antibody titer decreased from 40.6 IU/ml to 10.6 IU/ml. Conclusion. MMF was commonly used for the treatment of adult LN patients with acceptable efficacy and safety in Japan.

AB - Objectives. Mycophenolate mofetil (MMF) is used as one of the standard induction/maintenance protocols for lupus nephritis (LN). However, MMF has not been approved for treating LN in any country, resulting in worldwide off-label use of this immunosuppressant. In order to clarify the real-world use of MMF as a treatment for LN in Japan, Japan College of Rheumatology surveyed the use of MMF in daily clinical practice. Methods. Adult patients with LN who visited enrolled hospitals from October 2008 to September 2013 were surveyed for the initial, maximum, and maintenance doses of MMF. The safety and efficacy of MMF were retrospectively evaluated. Results. One hundred and thirty-seven LN patients including 116 females were enrolled. The median of initial, maximum, and maintenance doses of MMF were 1.0 g/day, 1.5 g/day, and 1.0 g/day, respectively. Sixty-one adverse events were reported in 39 patients during the follow-up period. Median urine protein level decreased from 1.89 g/gCr to 0.21 g/gCr, meanC3 level increased from 66.4 mg/dl to 80.3 mg/dl, and median anti-DNA antibody titer decreased from 40.6 IU/ml to 10.6 IU/ml. Conclusion. MMF was commonly used for the treatment of adult LN patients with acceptable efficacy and safety in Japan.

KW - Induction therapy

KW - Mycophenolate mofetil

KW - Mycophenolic acid

KW - Proliferative lupus nephritis

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84946838972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946838972&partnerID=8YFLogxK

U2 - 10.3109/14397595.2015.1031444

DO - 10.3109/14397595.2015.1031444

M3 - Article

VL - 25

SP - 854

EP - 857

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 6

ER -